iShares MSCI Canada (TSX) vs Revolution Medicines Inc. Common Stock — how do they compare? iShares MSCI Canada (TSX) trades at $58.83 (market cap $6.99B), while Revolution Medicines Inc. Common Stock trades at $191.91 (market cap $40.32B). The key difference: Revolution Medicines Inc. Common Stock is far larger — about 5.8× iShares MSCI Canada (TSX)'s market cap, and Revolution Medicines Inc. Common Stock is trading nearer its 52-week high, iShares MSCI Canada (TSX) nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Canada (TSX) for 57 Days and Revolution Medicines Inc. Common Stock for 0 Days on average.
| EWC | RVMD | |
|---|---|---|
Market Cap | $6.99B | $40.32B |
Volume | 1,625,847 | 4,855,734 |
Sector | Broad Market / Factor | Health |
52-Week High | $62.64 | $221.15 |
52-Week Low | $49.72 | $47.50 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | — | $37.02B |
Signals from Pluang's Aura AI — not financial advice
EWC trades at $57.94, down 2.1% today amid a bearish technical signal with moving averages indicating selling pressure. The stock lacks disclosed financial ratios, limiting fundamental clarity. Recent news highlights trade tensions between the U.S. and Canada, with potential impacts on cross-border economic activity and market sentiment.
The outlook is clouded by geopolitical risks from U.S.-Canada trade disputes, which could pressure performance. Investment opportunities hinge on resolution of trade frictions and improved economic data. Key risks include prolonged trade uncertainty and volatility from political developments.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →Revolution Medicines develops precision medicines for cancer. Its programs focus on targeting RAS-driven cancers and related signaling pathways.
Read more on RVMD →